Results 111 to 120 of about 3,046 (215)

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk

JACC: Case Reports
Background: Treatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging.
Omar M. Abdelfattah, MD, Robyn Bryde, MD, Kutaiba Nazif, MD, Matthew W. Martinez, MD   +3 more
doaj   +1 more source

Forest plot showing changes in NT-proBNP of Mavacamten group compared to placebo at random effect.

Forest plot showing changes in NT-proBNP of Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +1 more source

Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients As early as one week of treatment in obstructive hypertrophic cardiomyopathy.

International Journal of Cardiology
BACKGROUND Real-world data on the efficacy of mavacamten, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), are relatively scarce, particularly in patients with extreme left ventricular outflow tract (LVOT) gradients and ...
V. Nagy, G. Rácz, H. Takács, K. Boda, B. Polestyuk, N. Schvartz, L. D. Vidács, Jenő Antal Pintér, A. Pálinkás, Á. Kormányos, Tamás Szűcsborús, J. Borbás, T. Szili-Torok, R. Sepp   +13 more
semanticscholar   +1 more source

Forest plot showing changes in LAVI of the Mavacamten group compared to placebo at random effect.

Forest plot showing changes in LAVI of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system

Open Heart
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients’ symptomatic ...
Tingting Wu, Jiahao Zhang, Jialing Qian, Qingqing Jiang   +3 more
doaj   +1 more source

Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial.

American Heart Journal
BACKGROUND Mavacamten, a first-in-class cardiac myosin inhibitor, is approved internationally for the treatment of symptomatic adult patients with obstructive hypertrophic cardiomyopathy (HCM) and has been shown to improve cardiac function and symptoms ...
Joseph W. Rossano, C. Canter, C. Wolf, N. Favatella, Jeffrey Lockman, Shilpa Puli, Atefeh Javidialsaadi, J. Dyme, Christina Crevar, S. Mital   +9 more
semanticscholar   +1 more source

Mavacamten

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Forest plot showing NYHA grade improvement in the Mavacamten group compared to placebo at random effect.

Forest plot showing NYHA grade improvement in the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Forest plot showing a reduction in LVEF of Mavacamten compared to placebo at random effect.

Forest plot showing a reduction in LVEF of Mavacamten compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source